Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy

[1]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[2]  J. Badimón,et al.  Beginning to understand high-density lipoproteins. , 2014, Endocrinology and metabolism clinics of North America.

[3]  H. Kempen,et al.  Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size , 2014, Journal of lipids.

[4]  G. Jarvik,et al.  Quantification of HDL particle concentration by calibrated ion mobility analysis. , 2014, Clinical chemistry.

[5]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[6]  D. Rader,et al.  Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome , 2014, Circulation research.

[7]  T. Dawber,et al.  The Framingham Study , 2014 .

[8]  A. Nègre-Salvayre,et al.  Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids: Relevance to Cellular Cholesterol Efflux, Antioxidative, Antithrombotic, Anti-Inflammatory, and Antiapoptotic Functionalities , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[9]  A. Kontush,et al.  Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.

[10]  Amy S. Shah,et al.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond1 , 2013, Journal of Lipid Research.

[11]  D. Corella,et al.  Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. , 2013, Atherosclerosis.

[12]  P. Barter,et al.  Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges , 2013, Circulation.

[13]  P. Ridker,et al.  High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.

[14]  S. Plassmann,et al.  Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys[S] , 2013, Journal of Lipid Research.

[15]  W. Simpson,et al.  Effects of Wheat and Oat-Based Whole Grain Foods on Serum Lipoprotein Size and Distribution in Overweight Middle Aged People: A Randomised Controlled Trial , 2013, PloS one.

[16]  P. Wilson,et al.  Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients , 2013, Journal of the American Heart Association.

[17]  R. Rosenson,et al.  Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield , 2013, Current Atherosclerosis Reports.

[18]  M. Landray,et al.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[19]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[20]  C. Ballantyne,et al.  Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). , 2012, Journal of clinical lipidology.

[21]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[22]  Samia Mora,et al.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). , 2012, Journal of the American College of Cardiology.

[23]  S. Grundy.  Use of emerging lipoprotein risk factors in assessment of cardiovascular risk. , 2012, JAMA.

[24]  R. Collins,et al.  Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.

[25]  Zahi A Fayad,et al.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.

[26]  R. Krauss,et al.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S] , 2012, Journal of Lipid Research.

[27]  C. Ballantyne,et al.  Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. , 2012, American heart journal.

[28]  A. Kontush,et al.  High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics , 2012 .

[29]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[30]  M. Shabbout,et al.  Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. , 2011, Journal of clinical lipidology.

[31]  A. Kontush,et al.  Biological activities of HDL subpopulations and their relevance to cardiovascular disease. , 2011, Trends in molecular medicine.

[32]  Patty W Siri-Tarino,et al.  Effects of Diet on High-Density Lipoprotein Cholesterol , 2011, Current atherosclerosis reports.

[33]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[34]  Allen J. Taylor,et al.  Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. , 2011, Journal of the American College of Cardiology.

[35]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[36]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[37]  A. Kontush,et al.  Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities , 2010, Current opinion in lipidology.

[38]  J. Nofer,et al.  High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis , 2010, Clinical and experimental pharmacology & physiology.

[39]  M. Phillips,et al.  High-density lipoprotein heterogeneity and function in reverse cholesterol transport , 2010, Current opinion in lipidology.

[40]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[41]  A. Tall,et al.  The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis D.M. is supported by a grant from the Philippe Foundation. Published, JLR Papers in Press, November 20, 2008. , 2009, Journal of Lipid Research.

[42]  W. Kraemer,et al.  Carbohydrate Restriction has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet , 2009, Lipids.

[43]  J. Hsia,et al.  Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome , 2009, Diabetes Care.

[44]  N. Wareham,et al.  High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.

[45]  W. H. Benner,et al.  Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. , 2008, Clinical chemistry.

[46]  J. Tomassini,et al.  Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. , 2008, Journal of the American College of Cardiology.

[47]  Christina Lindahl,et al.  High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. , 2008, Journal of the American College of Cardiology.

[48]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[49]  L. Kuller,et al.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. , 2007, Atherosclerosis.

[50]  G. Fonarow,et al.  The paradox of dysfunctional high-density lipoprotein , 2007, Current opinion in lipidology.

[51]  W. Cromwell,et al.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.

[52]  R. Karas,et al.  Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. , 2006, The American journal of cardiology.

[53]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[54]  T. Dudley,et al.  Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. , 2006, International journal of cardiology.

[55]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[56]  P. Barter,et al.  Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. , 2006, Journal of the American College of Cardiology.

[57]  B. Hansel,et al.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia , 2005, Diabetologia.

[58]  W. Yancy,et al.  A Low-Carbohydrate, Ketogenic Diet versus a Low-Fat Diet To Treat Obesity and Hyperlipidemia , 2004, Annals of Internal Medicine.

[59]  G. Assmann,et al.  High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. , 2003, Biochemical and biophysical research communications.

[60]  A. Kontush,et al.  Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[61]  W. Kraus,et al.  Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.

[62]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[63]  P. Barter,et al.  Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells , 2002, Current opinion in lipidology.

[64]  J. Oram.  The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for cardiovascular disease. , 2002, Trends in cardiovascular medicine.

[65]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[66]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[67]  E. Schaefer,et al.  Distribution of ApoA-I–Containing HDL Subpopulations in Patients With Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[68]  H. Mabuchi,et al.  Cholesteryl ester transfer protein and atherosclerosis , 2000, Current opinion in lipidology.

[69]  José A Fernández,et al.  High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.

[70]  W. Castelli.  Lipids, risk factors and ischaemic heart disease. , 1996, Atherosclerosis.

[71]  D. Stafforini,et al.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.

[72]  M Ala-Korpela,et al.  1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. , 1994, Journal of lipid research.

[73]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[74]  C. Sloop,et al.  Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. , 1993, Biochimica et biophysica acta.

[75]  R. Stocker,et al.  High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Mensink,et al.  Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[77]  N. Le,et al.  Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. , 1988, Journal of lipid research.

[78]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[79]  J. Albers,et al.  Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. , 1982, Journal of lipid research.

[80]  C. Fielding,et al.  Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system. , 1982, The Medical clinics of North America.

[81]  P. Demacker,et al.  Measurement of high-density lipoprotein cholesterol in serum: comparison of six isolation methods combined with enzymic cholesterol analysis. , 1980, Clinical chemistry.

[82]  A. Gotto,et al.  Characterization of human high density lipoproteins by zonal ultracentrifugation. , 1980, The Journal of biological chemistry.

[83]  H. Eder,et al.  Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. , 1951, The American journal of medicine.

[84]  H. Eder,et al.  Protein-lipid relationships in human plasma. I. In normal individuals. , 1951, The American journal of medicine.

[85]  M. Jensen,et al.  Acute changes in lipoprotein subclasses during exercise. , 2014, Metabolism: clinical and experimental.

[86]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[87]  D. Gordon,et al.  High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .

[88]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[89]  R. Gregg,et al.  Apolipoproteins and lipoproteins in human plasma: an overview. , 1988, Clinical chemistry.

[90]  J. Fruchart,et al.  Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. , 1987, Clinical chemistry.